Supriya Lifescience Limited — Board Meeting, 09-02-2026: Outcome of Board Meeting
09-02-2026 | 07:25 pm
09-02-2026 | 07:25 pm
Supriya Lifescience's board approved standalone Q3 FY26 results: Revenue from Operations ₹206.44 Cr, Profit ₹49.68 Cr. They also re-appointed Dr. Neelam Yashpal Arora and appointed Mr. Manish Panchal and Mr. Kothandaraman Hari as Independent Directors for five years.
No comments yet. Be the first to comment!
